TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33478567
Drug: Triple low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Triple low-dose antihypertensive drug combination
Study: 33478567
Drug: Dual drug
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual drug combination
Study: 33478567
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (monotherapy followed by dual treatment)
Study: 33478567
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care with optional dose titration after 4 and 8 weeks
Study: 34182929
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia (pre-operative acetaminophen and gabapentin, intra-operative flurbiprofen and ropivacaine, post-operative acetaminophen and celecoxib)
Study: 35420672
Drug: Bortezomib added
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib added to decitabine therapy
Study: 35420672
Drug: Dependence in
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dependence in instrumental activities of daily living
Study: 39118415
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy
Study: 32679201
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow treatment
Study: 35650612
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Gyejibokryeong-hwan (GBH)
Study: 35650612
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Gyejibokryeong-hwan (GBH)
Study: 32217561
Drug: azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: azithromycin 500 mg one time per day for 3 days
Study: 32217561
Drug: amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin 1 g three times per day for 5 days
Study: 32217561
Drug: standard-of-care (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-of-care (no immediate antibiotic)
Study: 32217561
Drug: azithromycin and
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin and amoxicillin (combined)
Study: 34865452
Drug: rb‐bFGF gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: rb‐bFGF gel
Study: 34865452
Drug: gel matrix
Normalized name: Sil_k Pad Gel Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel matrix
Study: 34717154
Drug: IRX-2 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRX-2 regimen (low dose 300 mg/m2 cyclophosphamide on day 1, followed by 10 days of regional perilymphatic IRX-2 cytokine injections and daily oral indomethacin, zinc, and omeprazole)
Study: 35040196
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (INT)
Study: 35040196
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CONV)
Study: 35927828
Drug: Honey-flavoured syrup
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey-flavoured syrup placebo
Study: 33653284
Drug: 7-day proton-pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy (STT)
Study: 36434615
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS) with a high-protein-high calorie mixture containing immunonutrients (Impact®) plus nutritional counseling
Study: 32636985
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression plus standard compression therapy
Study: 32636985
Drug: Control (compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (compression therapy alone)
Study: 34347947
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg every 4 weeks
Study: 34347947
Drug: Mepolizumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 300 mg every 4 weeks
Study: 34347947
Drug: Mepolizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (both doses)
Study: 32877266
Drug: Patching therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching therapy (14–42 hours per week)
Study: 35963274
Drug: NVX-CoV2373 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 (5 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant)
Study: 34461058
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen therapy (Oxygen, n = 26)
Study: 34461058
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Air; n = 26)
Study: 32935460
Drug: Solriamfetol 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 900 mg
Study: 32719868
Drug: Vadadustat 150
Normalized name: vadadustat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat 150 mg
Study: 32719868
Drug: Vadadustat 300
Normalized name: vadadustat 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat 300 mg
Study: 32719868
Drug: Vadadustat 600
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vadadustat 600 mg
Study: 32719868
Drug: Vadadustat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat (all doses)
Study: 35979054
Drug: Esketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.5 mg/kg + 2 ml normal saline)
Study: 35022058
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) combined with routine nursing
Study: 35443830
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dose of the COMT inhibitor tolcapone
Study: 34022150
Drug: R-CHOP (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1·4 mg/m2, prednisone 100 mg) every 21 days for up to six cycles
Study: 34695800
Drug: Mass azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mass azithromycin distribution (specific dosage and duration not mentioned)
Study: 32717058
Drug: Oral D/L-3-Hydroxybutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D/L-3-Hydroxybutyrate
Study: 32717058
Drug: Matched intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched intravenous D/L-3-Hydroxybutyrate
Study: 35830550
Drug: OnabotulinumtoxinA +
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA + hydrogel treatment groups
Study: 32507146
Drug: TMJ manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMJ manual therapy plus exercise therapy in addition to routine physiotherapy for neck pain (Group B)
Study: 35393165
Drug: augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: augmentation with aripiprazole for 12 additional weeks
Study: 35791477
Drug: Post-discharge pharmacist-led
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge pharmacist-led follow-up (weekly for 6 months)
Study: 35791477
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication guidance (control group)
Study: 32135488
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy with Tegenaria Domestica (domestic house spider)
Study: 35116067
Drug: Guilingji capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guilingji capsules (GLJC)
Study: 35116067
Drug: Ginkgo extract
Normalized name: Ginkgo extract
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo extract tablets
Study: 33190679
Drug: Levetiracetam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (40 mg/kg)
Study: 34701328
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy + cisplatin concurrent radiochemotherapy
Study: 34701328
Drug: PF adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF adjuvant chemotherapy + cisplatin concurrent radiochemotherapy
Study: 616279865
Drug: NRB-Flush (non-rebreather
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRB-Flush (non-rebreather mask with flush rate oxygen >40 L/min)
Study: 34131914
Drug: Magnetic seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic seizure therapy (MST)
Study: 35568246
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose RT (EDRT; 70.2 Gy/39 fractions/5 days a week)
Study: 35568246
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose RT (SDRT; 55.8 Gy/31 fractions/5 days a week)
Study: 35568246
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose RT (EDRT)
Study: 35568246
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose RT (SDRT)
Study: 33200303
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (S-1 plus cisplatin) followed by D2 gastrectomy plus adjuvant chemotherapy with S-1 (Arm B)
Study: 33200303
Drug: D2 surgery
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 surgery followed by adjuvant chemotherapy with S-1 (Arm A)
Study: 32473020
Drug: Hydroxychloroquine sulphate
Normalized name: Hydroxychloroquine sulphate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulphate 400mg twice daily on Day 1, then 400mg once daily from Day 2 to Day 10
Study: 93204632
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (3 million units three times weekly)
Study: 93204632
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (3 million units three times weekly) after prednisolone withdrawal
Study: 35438151
Drug: Vicagrel 20/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel 20/5 mg (LD/MD)
Study: 35438151
Drug: Vicagrel 24/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel 24/6 mg
Study: 35438151
Drug: Vicagrel 30/7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel 30/7.5 mg
Study: 35438151
Drug: Clopidogrel 300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300/75 mg
Study: 32035053
Drug: CaniLeishÂ® vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaniLeishÂ® vaccine, n = 85
Study: 34223754
Drug: Complex treatment
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex treatment including lymphatic drainage kinesis‐taping and low-frequency pulse magnetic therapy
Study: 33745865
Drug: Veliparib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (120 mg twice daily) during chemoradiotherapy (CRT)
Study: 35092305
Drug: KY1005 (0.006,
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY1005 (0.006, 0.018, 0.05, 0.15, 0.45, 1.35, 4, or 12 mg/kg)
Study: 35092305
Drug: KY1005 (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY1005 (0.45 mg/kg and above)
Study: 32741143
Drug: Low-dose Methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Methotrexate (target dose 15-20 mg/week)
Study: 35923827
Drug: CDP-choline (Rischiaril®
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (Rischiaril® Forte, 1,000 mg of citicoline sodium salt)
Study: 35923827
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group - CG)
Study: 33819066
Drug: Budesonide orodispersible
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide orodispersible tablets
Study: 32048131
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) intravenously for 72 hours (150 mg/kg/h for 1 hour, followed by 12.5 mg/kg/h for 4 hours, followed by 6.25 mg/kg for 67 hours)
Study: 33587403
Drug: Viloxazine extended-release
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine extended-release (700 mg) + Lisdexamfetamine (50 mg)
Study: 33587403
Drug: Lisdexamfetamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamfetamine (50 mg)
Study: 33587403
Drug: Viloxazine extended-release
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine extended-release (700 mg)
Study: 35063243
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg per day for 24 weeks)
Study: 35987546
Drug: Telephone-based Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based Behavioral Activation (BA) intervention, eight weekly individual sessions
Study: 32097450
Drug: Whole-grain rye
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain rye diet (± SDG supplements)
Study: 35366138
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific therapy (control group)
Study: 34154965
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of black pepper essential oil
Study: 36273210
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of strengthening exercises and functional swallowing therapy (group 2)
Study: 36273210
Drug: Non-invasive brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive brain stimulation added to the combination of strengthening exercises and functional swallowing therapy (group 3)
Study: 33205809
Drug: Ciraparantag (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag (single IV dose at peak concentrations of the anticoagulant)
Study: 35859298
Drug: Nano-silymarin (SinaLive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-silymarin (SinaLive soft gel, 70 mg silymarin as nanomicelles, three times daily for two weeks)
Study: 35859298
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three times daily for two weeks)
Study: 35534091
Drug: Vita 500
Normalized name: Vita-Respa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vita 500 (liquid formulation)
Study: 32804621
Drug: i‐PROACTIF intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: i‐PROACTIF intervention (Integrated PRimary care and Occupational therapy for Aging and Chronic disease Treatment to preserve Independence and Functioning)
Study: 33488071
Drug: BDP/FF/G DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/G DPI (100/6/10µg via DPI, two inhalations twice daily for four weeks)
Study: 33488071
Drug: BDP/FF/G pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/G pMDI (100/6/10µg via pMDI, two inhalations twice daily for four weeks)
Study: 33488071
Drug: BDP/FF (100/6µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF (100/6µg via pMDI, two inhalations twice daily for four weeks)
Study: 34528079
Drug: secukinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab (300 or 150 mg weekly, then 4-weekly thereafter)
Study: 35313935
Drug: App-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based intervention (HAPPYTEEN) based on Transtheoretical Model (TTM) and Cognitive-Behavioral Therapy (CBT) delivered over 8 sessions for 2 months
Study: 33991702
Drug: Manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative therapy of sacral torsion
Study: 32208117
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) transfersomal gel
Study: 32208117
Drug: Free MB
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free MB gel
Study: 35315874
Drug: Aspirin (n=565)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (n=565)
Study: 35315874
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor (n=455)
Study: 35315874
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy (control; n=529)
Study: 32556176
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod cream followed by intradermal HBVv (IMQ + ID)
Study: 32556176
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous cream (placebo) followed by intradermal HBVv (AQ + ID)
Study: 32556176
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous cream followed by intramuscular HBVv (AQ + IM)
Study: 33573341
Drug: iMBI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: iMBI plus treatment-as-usual
Study: 35961614
Drug: Cooking Matters
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooking Matters for Diabetes intervention (6-week program with weekly food provision of 4 servings)
Study: 35026880
Drug: Habb-e-Asab (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habb-e-Asab (250 mg twice a day for 45 days)
Study: 35026880
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg twice a day for 45 days)
Study: 33961310
Drug: Domagrozumab 5
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 5 mg/kg
Study: 33961310
Drug: Domagrozumab 20
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 20 mg/kg
Study: 33961310
Drug: Domagrozumab 40
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 40 mg/kg
Study: 33961310
Drug: Domagrozumab (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab (after switching from 5 mg/kg to 40 mg/kg)
Study: 33180565
Drug: SIFT IT
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIFT IT group treatment program (14-week duration)
Study: 36398695
Drug: Physiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy plus corticosteroid injection (combined), single injection 3-6 days before physiotherapy
Study: 36384815
Drug: Delivering e‐version
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivering e‐version of oral health education pamphlets to adolescents
Study: 32877578
Drug: IONIS-PKK-LRx administered
Normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-PKK-LRx administered at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months after initial treatment with IONIS-PKKRx for 12 to 16 weeks.
Study: 32877578
Drug: IONIS-PKKRx administered
Normalized name: IONIS SOD1Rx
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-PKKRx administered weekly subcutaneous injections for 12 to 16 weeks.
Study: 33176129
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow (NHF) system at 2 kg/L/minute, up to a maximum of 30 L/minute
Study: 33176129
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula (NC) group at 5 L/minute
Study: 32459987
Drug: Memory and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory and learning of treatment contents
Study: 35367003
Drug: ZyCoV-D vaccine
Normalized name: ZYCOV-D
DrugBank: ZYCOV-D (DB15892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZyCoV-D vaccine (2 mg per dose, 3 doses administered intradermally via a needle-free injection system 28 days apart)
Study: 35367003
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 doses administered intradermally via a needle-free injection system 28 days apart)
Study: 35367003
Drug: ZyCoV-D vaccine
Normalized name: ZYCOV-D
DrugBank: ZYCOV-D (DB15892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZyCoV-D vaccine
Study: 34783725
Drug: Paracetamol 1000mg
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1000mg
Study: 35565844
Drug: SAx (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAx (oral supplement containing Hydroxytyrosol and Punicalagin)
Study: 34863109
Drug: Dexmedetomidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1 μg/kg/hour)
Study: 32727496
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of ranibizumab (0.5 mg) alone (IVOM-Group)
Study: 32727496
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of ranibizumab (0.5 mg) with additional micropulse diode laser (IVOM+Laser-Group)
Study: 35037597
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with nortriptyline
Study: 32361977
Drug: IMU‐838 (vidofludimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMU‐838 (vidofludimus calcium) single doses (10-40 mg fasting, 10 mg fed)
Study: 32361977
Drug: IMU‐838 (vidofludimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMU‐838 (vidofludimus calcium) multiple doses (30-50 mg)
Study: 33542279
Drug: 3‐nitrooxypropanol (3‐NOP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐nitrooxypropanol (3‐NOP), administered daily from birth until three weeks post‐weaning (week 14)